Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED WITH ANAKINRA.

Journal of cardiovascular pharmacology·2026
Same author

INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED WITH ANAKINRA.

medRxiv : the preprint server for health sciences·2026
Same author

Cost-Effectiveness Analysis of Artificial Intelligence-Driven Risk Stratification in Patients With Diabetic Kidney Disease in the US Veterans Population.

Kidney medicine·2026
Same author

Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Patients With Obesity-Related Heart Failure With Preserved Ejection Fraction: The UFA-Preserved2 Randomized Controlled Crossover Study.

Circulation. Heart failure·2025
Same author

Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra.

Circulation. Heart failure·2025
Same author

Ivabradine and Atrial Fibrillation Incidence: A Nested Matching Study.

JACC. Advances·2025

Related Experiment Video

Updated: Jul 9, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
08:21

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Medication nonadherence: an unrecognized cardiovascular risk factor.

Mark A Munger1, Benjamin W Van Tassell, Joanne LaFleur

  • 1Departments of Pharmacotherapy and Internal Medicine, University of Utah, Salt Lake City, Utah, USA. mmunger@hsc.utah.edu

Medgenmed : Medscape General Medicine
|December 20, 2007
PubMed
Summary

Medication nonadherence is a major problem in chronic disease management, especially for hypertension. Improving patient and prescriber awareness is key to better health outcomes and reduced healthcare costs.

Related Experiment Videos

Last Updated: Jul 9, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans
08:21

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Area of Science:

  • Pharmacology
  • Public Health
  • Cardiology

Background:

  • Medication nonadherence is a pervasive issue affecting one-third to one-half of patients across various conditions.
  • Nonadherence significantly impairs treatment outcomes, leading to increased morbidity and mortality, as seen in post-myocardial infarction patients.
  • The economic burden of medication nonadherence is substantial, contributing to millions in healthcare costs and hospital admissions.

Purpose of the Study:

  • To review the prevalence and impact of medication nonadherence as a risk factor in chronic disease management.
  • To specifically focus on nonadherence in the context of antihypertensive medications and its link to cardiovascular disorders.
  • To discuss factors contributing to nonadherence and strategies for improving medication adherence.

Main Methods:

  • Literature review examining the prevalence of nonadherence in chronic diseases.
  • Analysis of factors influencing nonadherence, including drug choice, concomitant medications, tolerability, and treatment duration.
  • Discussion of interventions and strategies to enhance medication adherence.

Main Results:

  • Nonadherence is a significant, often unrecognized, risk factor in hypertension, contributing to poor blood pressure control and vascular complications like heart failure and stroke.
  • High nonadherence rates are observed across diverse patient populations, with the initial months of therapy showing the highest discontinuation rates.
  • Barriers to adherence are multifactorial, encompassing complex regimens, convenience, behavioral aspects, and the treatment of asymptomatic conditions.

Conclusions:

  • Improving medication adherence requires increased awareness among both patients and healthcare prescribers.
  • Identifying indicators of nonadherence within patient populations is crucial for targeted interventions.
  • Strategies to improve adherence, including enhanced patient education and healthcare team support, are essential for effective chronic disease management.